
Please try another search
By Davit Kirakosyan
Jefferies upgraded Moderna (NASDAQ:MRNA) to Buy from Hold and raised its price target to $275.00 from $170.00 on a significant new pipeline story and catalysts ahead. “New story is now PCV cancer vaccine opportunity, Phase III RSV data coming up, doublet and triplet virus vaccines in 2023,” mentioned the analysts.
Atlantic Equities upgraded Warner Music Group (NASDAQ:WMG) to Overweight from Neutral and price target to $41.00 from $34.00, noting it sees additional upside if the music industry can deliver sustainable pricing growth.
JPMorgan upgraded Glaukos Corp (NYSE:GKOS) to Neutral from Underweight and cut its price target to $42.00 from $48.00, noting it is tentatively optimistic that stabilizing trends in the base business should support modest growth in 2023 ahead of an iDose launch that has been anticipated since the 2015 IPO.
MoffettNathanson upgraded Verizon Communications (NYSE:VZ) to Market Perform from Underperform with a price target of $41.00.
Want to get this news first? Upgrade to InvestingPro for real-time market coverage.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.